产品介绍： MSX-122是一种新型的CXCR4部分拮抗剂，IC50约为10 nM。 Information MSX-122 is a novel small molecule and partialCXCR4antagonist (IC50~10 nM). Targets CXCR4 ~10 nM In vitro MSX-122 is also incapable of blocking the binding of 125I-labeled CXCL12 to CXCR4. MSX-122 appears to be insufficiently large to block all binding sites between CXCR4 and CXCL12. MSX-122 blocks certain CXCR4 functions via binding to the CXCL12-binding site and interfering with CXCR4/CXCL12-mediated signaling. MSX-122 can intervene in the Gαi-signaling pathway (cAMP modulation), but not the Gq-pathway (calcium flux). In vivo MSX-122 blocks bleomycin-induced lung fibrosis involving chemotaxis and homing of CXCR4-positive mesenchymal progenitor cells into the lungs. MSX-122 exhibits anti-inflammatory activity in a carrageenan-induced paw edema model. MSX-122 blocks lung metastasis of breast cancer and SCCHN, and liver metastasis of uveal melanoma in vivo. Cell Research(from reference) Cell lines：MDA-MB-231 cells Concentrations：1, 10, 100, and 1000 nM Incubation Time：15 mins